{
    "key_points": [
        "FDA amended EUAs for Pfizer-BioNTech and Moderna COVID-19 Vaccines for an additional dose for certain immunocompromised individuals.",
        "CDC's Advisory Committee on Immunization Practices to discuss further recommendations for immunocompromised individuals.",
        "Additional vaccine dose aimed at solid organ transplant recipients or those with equivalent immunocompromise, not for general population.",
        "Acting FDA Commissioner Janet Woodcock emphasizes the importance of this step for the vulnerable group amid COVID-19 wave.",
        "Immunocompromised individuals have a reduced ability to fight infections, making them more susceptible to COVID-19.",
        "Third vaccine dose may increase protection for these individuals, but physical precautions are still recommended.",
        "FDA advises immunocompromised individuals to discuss monoclonal antibody treatment options for COVID-19 with their healthcare providers.",
        "Pfizer-BioNTech authorized for ages 12 and older, Moderna authorized for 18 and older, both require two initial shots.",
        "Third dose approved to be given at least 28 days after the two-dose regimen to eligible individuals.",
        "EUA amendments issued to Pfizer Inc. and ModernaTX Inc."
    ],
    "spokespersons": [
        "Janet Woodcock (Acting FDA Commissioner)"
    ],
    "article_type": "press release",
    "dateline": "",
    "audience": "general public",
    "stance": "neutral"
}